CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $2.1B, above the global median of $1.15B
- FinancialsAltman Z-Score 14.5: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.64%
Annual Rate
CNY 0.22Paid semi-annual
Payout Ratio
35.0%Sustainable
Last Ex-Dividend
Jun 9, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
14.11BCNY2.10B · vs all stocks (USD)
Trailing P/E
91.75xvs Biotechnology peers
Revenue (TTM)
830.61MCNY123.52M · vs all stocks (USD)
Profit Margin
19.23%vs Biotechnology peers
Beta
0.8560xvs all stocks
52-Week Change
84.58%vs all stocks
Market Capitalization
14.11BCNY2.10B · vs all stocks (USD)
Enterprise Value
13.31BCNY1.98B · vs all stocks (USD)
Trailing P/E
91.75xvs Biotechnology peers
Forward P/E
57.32xvs Biotechnology peers
Price to Sales (TTM)
18.12xvs Biotechnology peers
Price to Book (MRQ)
6.32xvs Biotechnology peers
Enterprise to Revenue
16.02xvs Biotechnology peers
Enterprise to EBITDA
54.44xvs Biotechnology peers
Gross Margin
64.07%vs Biotechnology peers
Profit Margin
19.23%vs Biotechnology peers
Operating Margin
24.86%vs Biotechnology peers
Return on Assets (TTM)
3.88%vs Biotechnology peers
Return on Equity (TTM)
7.20%vs Biotechnology peers
Revenue (TTM)
830.61MCNY123.52M · vs all stocks (USD)
Revenue per Share (TTM)
2.08CNYUpdated Aug 21, 2026Quarterly Revenue Growth
21.80%vs Biotechnology peers
Gross Profit (TTM)
530.03MCNY78.82M · vs all stocks (USD)
EBITDA (TTM)
210.80MCNY31.35M · vs all stocks (USD)
Net Income (TTM)
159.76MCNY23.76M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
57.10%vs Biotechnology peers
Operating Cash Flow (TTM)
249.66MCNY37.13M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
76.76MCNY11.42M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.2200CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.64%vs all stocks
Payout Ratio
35.00%vs Biotechnology peers
Revenue
793.39MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
284.43MCNYFY2025 · Dec 31, 2025Gross Profit
508.96MCNYFY2025 · Dec 31, 2025Operating Income
181.99MCNY27.06M · vs all stocks (USD)
Pre-tax Income
164.92MCNYFY2025 · Dec 31, 2025Income Tax Expense
22.29MCNYFY2025 · Dec 31, 2025Net Income
142.64MCNYFY2025 · Dec 31, 2025EBIT
171.00MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
288.12MCNYFY2025 · Dec 31, 2025Research & Development
92.06MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
118.06MCNYFY2025 · Dec 31, 2025Other Operating Expenses
4.99MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
10.56MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
6.08MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.3500CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.3500CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
407.53MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
407.53MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
142.64MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
88.63MCNYFY2025 · Dec 31, 2025Free Cash Flow
-16.21MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
485.94MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
142.64MCNYFY2025 · Dec 31, 2025Other Non-cash Items
18.79MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-56.61MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-16.19MCNYFY2025 · Dec 31, 2025Capital Expenditures
-104.83MCNYFY2025 · Dec 31, 2025Purchase of Investments
-15.51MCNYFY2025 · Dec 31, 2025Sale of Investments
17.24MCNYFY2025 · Dec 31, 2025Other Investing Activity
-363.47MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-466.58MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
298.49MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-199.21MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-61.22MCNYFY2025 · Dec 31, 2025Other Financing Charges
-11.16MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
26.89MCNYFY2025 · Dec 31, 2025Shares Outstanding
410.00MSharesUpdated Aug 21, 2026Float Shares
159.11MSharesUpdated Aug 21, 2026% Held by Insiders
59.97%vs all stocks
% Held by Institutions
8.05%vs all stocks
Total Cash (MRQ)
1.09BCNY161.44M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.77CNYUpdated Aug 21, 2026Total Debt (MRQ)
259.51MCNY38.59M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1139xvs Biotechnology peers
Current Ratio (MRQ)
3.58xvs Biotechnology peers
Book Value per Share (MRQ)
5.81CNYUpdated Aug 21, 2026Total Assets
2.87BCNY426.06M · vs all stocks (USD)
Total Current Assets
1.75BCNYFY2025 · Dec 31, 2025Total Liabilities
637.87MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.11BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
110.73MCNYFY2025 · Dec 31, 2025Total Current Liabilities
527.14MCNYFY2025 · Dec 31, 2025Cash
484.36MCNYFY2025 · Dec 31, 2025Cash Equivalents
2.26MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
486.62MCNYFY2025 · Dec 31, 2025Other Short-term Investments
757.69MCNYFY2025 · Dec 31, 2025Accounts Receivable
384.96MCNYFY2025 · Dec 31, 2025Inventory
72.96MCNYFY2025 · Dec 31, 2025Accounts Payable
68.13MCNYFY2025 · Dec 31, 2025Short-term Debt
211.08MCNYFY2025 · Dec 31, 2025Long-term Debt
80.23MCNYFY2025 · Dec 31, 2025Common Stock (Book)
410.00MCNYFY2025 · Dec 31, 2025Retained Earnings
510.64MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.23BCNY331.21M · vs all stocks (USD)
Treasury Stock
16.02MCNYFY2025 · Dec 31, 202552-Week Low
12.89CNYUpdated Aug 21, 202652-Week High
43.47CNYUpdated Aug 21, 202652-Week Change
84.58%vs all stocks
Beta
0.8560xvs all stocks
50-Day MA
26.11CNYUpdated Aug 21, 2026200-Day MA
19.58CNYUpdated Aug 21, 2026Avg 10-Day Volume
25.17MSharesUpdated Aug 21, 2026Avg 30-Day Volume
17.88MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
0.4000CNYUpdated Aug 21, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 14.5: safe zoneNotable
Altman Z-Score: 14.50
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2.1B, above the global median of $1.15BNotable
Market cap (USD): 2,097,748,381.291Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Anhui Anke Biotechnology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Verano Holdings Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hanall Biopharma Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ab&B Bio-Tech Co., Ltd. (JS)
Tier 1ProductionApproval-Gated PipelineRule
Eris Lifesciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Axogen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Kalbe Farma Tbk. PT
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Weigao Blood Purification Products Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Monte Rosa Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Mabwell (Shanghai) Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Cupid Ltd.
2 interpretationsRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income Growth
Chaozhou Three-Circle Group Co. Ltd.
3 interpretationsCash Backing With Revenue And Income StreaksRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income Growth